Aqualyx

Aqualyx is a formulation of phosphatidylcholine and deoxycholate, used for intralipotherapy (injectable fat reduction). It is used as a medical device in some jurisdictions for localized fat reduction.

Aqualyx is an injectable solution primarily composed of deoxycholic acid, a secondary bile acid produced physiologically by the human body to emulsify dietary fats. Unlike exogenous hormonal agents that influence protein synthesis or androgen receptor signaling, Aqualyx functions exclusively through a localized physicochemical mechanism known as adipocytolysis. Upon injection into subcutaneous adipose tissue, the deoxycholic acid acts as a biological detergent, disrupting the integrity of the adipocyte cell membrane. By lowering the surface tension and solubilizing the phospholipid bilayer, the compound induces irreversible cell lysis, causing the membrane to rupture and release the stored triglycerides into the interstitial space.

The metabolic clearance of the resultant cellular debris is mediated by the local inflammatory response and the lymphatic system. Once the adipocyte membrane is compromised, intracellular enzymes and lipids are released, triggering the recruitment of macrophages to the site of injection. These phagocytic cells engulf the remnants of the adipocyte through a process of organized clearance, effectively processing the lipid content and facilitating its transport through the lymphatic vessels toward systemic circulation. From there, the fatty acids and glycerol are metabolized via beta-oxidation and hepatic processes, similar to the processing of dietary lipids.

This process is highly localized, meaning that Aqualyx does not interact with mTOR, IGF-1, or myostatin pathways, nor does it possess anabolic or anti-catabolic properties in skeletal muscle tissue. Because the mechanism of action is limited to membrane disruption, Aqualyx does not interfere with systemic enzymatic pathways such as aromatization or 5-alpha reductase, nor does it impact androgen receptor binding or mitochondrial oxidative capacity. Its pharmacological profile is characterized by high site-specificity and minimal systemic absorption; once the deoxycholate binds to the target adipose membranes, it is rapidly neutralized or diluted, preventing significant interference with surrounding connective tissue, bone, or muscle fascia.

The compound remains active only within the local depot for a brief period before being metabolized or excreted through normal bile acid pathways, ensuring that the physiological impact is confined to the targeted reduction of localized adipose volume without inducing systemic endocrine or metabolic alterations.

Aqualyx is a medical device in some jurisdictions. In the US it is not FDA-approved. It is not a controlled substance. Supply and administration by unlicensed individuals is illegal in most jurisdictions.

Products obtained outside of pharmaceutical supply chains often carry significant risks of microbial contamination, incorrect chemical concentrations, or the presence of hazardous impurities. To ensure safety and identity, users should seek independent third-party analytical reports using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify the concentration of deoxycholate and confirm the absence of toxic degradation products or bacterial endotoxins.